THE latest update to the Formulary Allocations list now includes chemotherapy venetoclax which is marketed as Venclexta and is approved for Australians with relapsed or refractory CLL under certain conditions.
In addition, ex-manufacturer prices have been updated for Efficient Funding of Chemotherapy.
See pbs.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Mar 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Mar 19
